Y-pegylated recombinant interferon alpha-2a - Amoytop Biotech/BioGeneric Pharma

Drug Profile

Y-pegylated recombinant interferon alpha-2a - Amoytop Biotech/BioGeneric Pharma

Alternative Names: YPEG-rhIFNα-2a - Amoytop Biotech/BioGeneric Pharma

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amoytop Biotech; BioGeneric Pharma
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants; Interferon alfa 2a stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Hepatitis C
  • No development reported Hepatitis B

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-B in China (SC, Irrigation)
  • 17 Apr 2016 Biomarkers information updated
  • 01 Nov 2010 Clinical trials in Hepatitis B in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top